Company XORTX Therapeutics Inc.

Equities

XRTX

CA98420Q3061

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Toronto S.E. Other stock markets 03:59:59 2024-04-26 pm EDT			5-day change	1st Jan Change
4.07 ^CAD	+12.43%		0.00%	+40.34%

Apr. 22	XORTX Therapeutics Announces Publication of Key Research in ADPKD in Peer-reviewed Journal	MT
Apr. 08	XORTX Therapeutics Inc. Appoints Abigail Jenkins to the Board of Directors	CI

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.

Number of employees: 3

Managers	Title	Age	Since
Allen Davidoff FOU	Founder	64	18-01-08
Jim Fairbairn DFI	Director of Finance/CFO	65	18-11-05
Stephen Haworth CTO	Chief Tech/Sci/R&D Officer	-	21-06-30
David MacDonald CTO	Chief Tech/Sci/R&D Officer	-	22-01-19
Stacy Evans PRN	Corporate Officer/Principal	-	22-11-15
Brian Mangal PRN	Corporate Officer/Principal	-	-
Charlotte May SEC	Corporate Secretary	-	-

Members of the board	Title	Age	Since
Paul van Damme BRD	Director/Board Member	-	18-01-24
Allen Davidoff FOU	Founder	64	18-01-08
Anthony Giovinazzo CHM	Chairman	67	22-06-05
Raymond Pratt BRD	Director/Board Member	73	21-12-19
William Farley BRD	Director/Board Member	68	21-05-11
Patrick Treanor BRD	Director/Board Member	-	Dec. 30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,998,848	1,917,354 ( 95.92 %)	0	95.92 %

Name	Equities	%	Valuation
Armistice Capital LLC 8.494 %	169,790	8.494 %	628 223 $
Prevail Partnerships LLC 5.433 %	108,591	5.433 %	401 787 $
Allen Davidoff 3.400 %	67,957	3.400 %	251 441 $
Anthony Giovinazzo 0.4815 %	9,625	0.4815 %	35 613 $
Paul van Damme 0.3557 %	7,110	0.3557 %	26 307 $
Jim Fairbairn 0.3475 %	6,946	0.3475 %	25 700 $
Ian Klassen 0.2377 %	4,751	0.2377 %	17 579 $
Osaic Wealth, Inc. 0.0577 %	1,153	0.0577 %	4 266 $
Amar Keshri 0.0472 %	944	0.0472 %	3 493 $
RBC Dominion Securities, Inc. 0.0262 %	523	0.0262 %	1 935 $

XORTX Therapeutics, Inc.

3710–33rd Street NW

T2L 2M1, Calgary

+403 455 7727

http://www.xortx.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.07

Average target price

Consensus

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
XORTX THERAPEUTICS INC.	+40.34%	8.62M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs